



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Equioxx 57mg Chewable Tablets for Horses Vm 44684/5001

•	22 March 2024	Change in the manufacturer of the active substance supported by an ASMF.
•	07 November 2023	Change in the batch size of the finished product.
•	16 November 2023	Addition of a manufacturing site for the manufacturing process of the finished product.
•	24 August 2023	Addition of a pack size of 1 cardboard box containing 60 tablets in blisters.
•	04 March 2022	Change in the address of the marketing authorisation holder from AUDEVARD, 2-46 rue Médéric, 92110, Clichy, France to AUDEVARD, 37-39 rue de Neuilly, 92110, Clichy, France. Change of the back-up procedure of the QPPV of an existing pharmacovigilance system as described in the DDPS.
•	22 April 2021	Deletion of a non-significant specification parameter of an excipient